| 16.02 -0.03 (-0.19%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 22.44 | 1-year : | 26.22 |
| Resists | First : | 19.21 | Second : | 22.44 |
| Pivot price | 17.1 |
|||
| Supports | First : | 13.24 | Second : | 9.55 |
| MAs | MA(5) : | 15.66 |
MA(20) : | 16.93 |
| MA(100) : | 14.59 |
MA(250) : | 11.72 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 59.6 |
D(3) : | 56.5 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 19.34 | Low : | 4.42 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CABA ] has closed above bottom band by 32.0%. Bollinger Bands are 60.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.24 - 16.3 | 16.3 - 16.35 |
| Low: | 14 - 14.07 | 14.07 - 14.12 |
| Close: | 15.94 - 16.05 | 16.05 - 16.15 |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Wed, 29 Nov 2023
Cabaletta Bio Inc Initiation - William Blair
Wed, 29 Nov 2023
Leslie's Posts Weak Earnings, Joins Las Vegas Sands, Verve ... - Markets Insider
Tue, 28 Nov 2023
Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates ... - Morningstar
Tue, 28 Nov 2023
Cabaletta Bio to Participate in the 6th Annual Evercore ISI ... - Yahoo Finance
Tue, 28 Nov 2023
Crude Oil Surges 2%; Tharimmune Shares Plummet - Cabaletta Bio (NASDAQ:CABA), Carbon Revolution (NASDAQ:C - Benzinga
Tue, 28 Nov 2023
Healthcare Stocks Making Moves Tuesday: RDHL, ICCM, GYRE, CDIO, AXLA, CABA, BDRX, SEEL - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 8.6 (%) |
| Held by Institutions | 71.9 (%) |
| Shares Short | 6,280 (K) |
| Shares Short P.Month | 5,190 (K) |
| EPS | -1.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32 % |
| Return on Equity (ttm) | -50.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -9.43 |
| PEG Ratio | 0 |
| Price to Book value | 4.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|